Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Balzarini

Showing results (1-10 of 672) with videos related to

Pageof 68
Sort By:
The Lancet. Infectious Diseases|October 29, 2005
Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIVJan Balzarini
Nature Reviews. Microbiology|July 17, 2007
Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapyJan Balzarini
Antiviral Chemistry & Chemotherapy|March 16, 2007
Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?Jan Balzarini
Current Opinion in HIV and AIDS|April 18, 2009
Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120Jan Balzarini
FEBS Letters|May 4, 2007
The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120Jan Balzarini
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replicationJan Balzarini, Christopher McGuigan
Expert Opinion on Therapeutic Targets|July 17, 2015
The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applicationsLeen Mathys, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|August 15, 2009
FV100 as a new approach for the possible treatment of varicella-zoster virus infectionChristopher McGuigan, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|October 23, 2013
Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitnessLeen Mathys, Jan Balzarini
Retrovirology|December 16, 2014
The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agentsLeen Mathys, Jan Balzarini
Pageof 68

Showing results (1-10 of 672) with videos related to

Sort By:
Pageof 68
The Lancet. Infectious Diseases|October 29, 2005
Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIVJan Balzarini
Nature Reviews. Microbiology|July 17, 2007
Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapyJan Balzarini
Antiviral Chemistry & Chemotherapy|March 16, 2007
Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?Jan Balzarini
Current Opinion in HIV and AIDS|April 18, 2009
Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120Jan Balzarini
FEBS Letters|May 4, 2007
The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120Jan Balzarini
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replicationJan Balzarini, Christopher McGuigan
Expert Opinion on Therapeutic Targets|July 17, 2015
The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applicationsLeen Mathys, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|August 15, 2009
FV100 as a new approach for the possible treatment of varicella-zoster virus infectionChristopher McGuigan, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|October 23, 2013
Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitnessLeen Mathys, Jan Balzarini
Retrovirology|December 16, 2014
The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agentsLeen Mathys, Jan Balzarini
Pageof 68